Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

Gut microbiota / Evidence-based microbiome knowledge (incl. AI chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

Non-Alcoholic Steatohepatitis (NASH / MASH)

Navigation

Non-Alcoholic Steatohepatitis (NASH) is a severe form of non-alcoholic fatty liver disease (NAFLD) characterized by hepatic steatosis, liver inflammation, ﬁbrosis and damage due to fat accumulation.
Zhu et al. 2013 Hepatology 57: 601-609
Ajmera & Loomba 2021 Mol Metab 50: 101167

Non-Alcoholic Steatohepatitis (NASH)
[AMPK Pathway / AMP-activated protein kinase (AMPK)](brain://p4UbdcTp_ES4Dnnqk2hgeQ/AmpkPathwayAMPactivatedProteinKinaseAmpk…

References (Sources)

Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis
Tacke 2018 Exp Opin Invest Drugs 27: 301-311
Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH.
Zhu et al. 2013 Hepatology 57: 601-609
Gut symbionts alleviate MASH through a secondary bile acid biosynthetic pathway
Nie et al. 2024 Cell 187(11): 2717-2734
Imaging Biomarkers of NAFLD, NASH, and Fibrosis
Ajmera & Loomba 2021 Mol Metab 50: 101167
Review
Inflammatory Mechanisms Underlying Nonalcoholic Steatohepatitis and the Transition to Hepatocellular Carcinoma
Peiseler & Tacke 2021
Review
NAFLD and Cardiovascular Diseases: A Clinical Review
Kasper et al. 2021 Clin Res Cardiol 110: 921-37
Review
Nonalcoholic steatohepatitis (NASH) cirrhosis: a snapshot of therapeutic agents in clinical development and the optimal design for clinical trials
Aggarwal et al. 2022 Expert Opin. Investig. Drugs 31: 163-172
Review